Oppenheimer analyst Suraj Kalia upgraded Boston Scientific (BSX) to Outperform from Perform with a price target of $125, up from $118, after assuming coverage of the name. The firm believes Boston Scientific offers one of the best large-cap growth stories in medical technology, driven by a “disciplined” acquisition strategy and strong execution. The company is not immune to macro headwinds, but its 11%-13% annual sales growth outlook is attractive, especially for a “well-diversified play,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific Announces Executive Retirement Plan Update
- Medtronic Stock (MDT) Slides Despite Corporate Re-Jig to Boost Ailing Valuation
- Buy Rating for Boston Scientific Amid Manageable Risks in ENDOTAK RELIANCE Leads
- Boston Scientific price target raised to $118 at Oppenheimer (July 24)
- Insider Moves: Charles Schwab, Phillips 66, NXP, Corning, Boston Scientific